When choosing a GLP-1, doctors consider your current weight, eating patterns, blood sugar levels, and metabolic history
The results of the RAPID-PsA study show that treatment with certolizumab pegol is effective in patients with PsA with rapid improvement in clinical signs and symptoms of PsA, including arthritis, enthesitis, dactylitis and skin involvement
Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence
L-Carnitine + EGCG Green Tea: A formula that goes beyond: 300mg L-Carnitine tartrate, a well-established nutrient for metabolic support, combined with 152mg of green tea extract standardized in EGCG, recognized in Italy for the drainage of body fluids and balance body weight
Glutathione supplements tend to make the most sense for a specific set of people, rather than being a universal daily essential
Biosci Biotechnol Biochem 69: 10491053
